Glaukos Priced, NYSE: GKOS

Sells micro-scale surgical stents for treating glaucoma.

Industry: Health Care

Latest Trade: $24.50 0.00 (0.0%)

First Day Return: +73.4%

Return from IPO: +36.1%

Industry: Health Care

We are an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world's leading causes of blindness. We have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. We launched theĀ iStent, our first MIGS device, in the United States in July 2012 and we are leveraging our platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression.
more less
IPO News for Glaukos
more
IPO Data
IPO File Date 05/12/2015
Offer Price $18.00
Price Range $16.00 - $17.00
Offer Shares (mm) 6.0
Deal Size ($mm) $108
IPO Data
IPO Date 06/24/2015
Offer Price $18.00
Price Range $16.00 - $17.00
Offer Shares (mm) 6.0
Deal Size ($mm) $108
Underwriters
more
Company Data
Headquarters Laguna Hills, CA
Founded 1998
Employees 126
Website www.glaukos.com